Oncology Brothers
@OncBrothers
Followers
16K
Following
17K
Statuses
4K
Practice changing discussions by community oncologists-Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer. OwnViews/NoMedAdvice.COI https://t.co/cJOjp0RvQE
Joined August 2021
See you tonight before #GU25 kicks off! How will this data change/reinforce our practice? - Bladder Ca - Prostate Ca - RCC *Join us in-person* 📅 Date: Feb 12 (Wednesday) ⏰ Time: 6:00-8:00PM PST 📝 #OncTwitter #MedTwitter #AdvInOnc25 @OncoAlert
0
10
32
RT @TiansterZhang: Was a pleasure discussing #prostatecancer w good friend #RahulAggarwal @UCSFCancer & @OncBrothers! Thanks for highlighti…
0
1
0
RT @Jani_Chinmay: Excited to join the @OncBrothers event for a great discussion on #GUOncology! @ASCO GU. Looking forward to engaging conve…
0
2
0
RT @SalvadorjcMD: Amazing start to #GU25. @OncBrothers discuss recommendations for real-world treatment recommendations in the context of…
0
5
0
RT @nsayeghmd: #GU25 Very insightful discussion about the evolving treatment landscape of mHSPC and mCRPC by @TiansterZhang and @rahulaggar…
0
6
0
RT @visheshkhannaMD: Great panel discussions at the @OncBrothers Advancements in Oncology #ASCOGU25 event. Always inspiring to hear from ex…
0
2
0
RT @bergsa83: Back in SF for #GU25 @ASCO starting off with a great event @OncBrothers to kick off the meeting! Bladder, prostate and renal…
0
3
0
@OncoAlert @TiansterZhang @BraunMDPhD @ERPlimackMD @AmandaNizamMD @DrRosenbergMSK We will miss you! Look forward to seeing some of the @OncoAlert faculty tonight and dissecting through the data. Appreciate the support!! 🙏🏽🙏🏽
0
0
4
RT @OncoAlert: Major FOMO Tonight not being able to attend this great event 🌉by our dear friend @OncBrothers 🧑⚕️🧑⚕️ with such amazing pa…
0
3
0
RT @DrSGraff: Who wants to do a little #BRCAbrief CME with me?? @OncoAlert @OncBrothers @ErikaHamilton9 @Dr_RShatsky @maryam_lustberg @Rho…
0
3
0
@Onco_Cifu88 @JaniceTNBCmets @imsmart420 @VKaklamani @CancerNetwrk @HemOncFellows @BijoyTelivala @RenoHemonc @SuyogCancer @DrSGraff @PTarantinoMD @stolaney1 @Neil_Iyengar @hoperugo Yes, absolutely! With curative intent/adjuvant settings, full dose and then down titrating is perhaps the right approach.
0
0
3
@JaniceTNBCmets @imsmart420 @VKaklamani @CancerNetwrk @HemOncFellows @BijoyTelivala @RenoHemonc @SuyogCancer @DrSGraff @PTarantinoMD @stolaney1 @Neil_Iyengar @hoperugo Glad to hear she is doing well now. Another caveat when using Cape/5FU (more heavily used in GI space) is testing for DPYD deficiency (practice on this also differs quite significantly but @weldeiry has been a strong voice in this space/testing for all comers).
0
0
2
0
2
0
@JaniceTNBCmets @imsmart420 @VKaklamani @CancerNetwrk @HemOncFellows @BijoyTelivala @RenoHemonc @SuyogCancer @DrSGraff @PTarantinoMD @stolaney1 @Neil_Iyengar @hoperugo In mBC, with palliative intent, I often discuss 7 on/7 off acknowledging this is small data for mBC but we have similar data in mCRC (better tolerated, less dose interruptions, without compromising outcomes… though this was also retrospective analysis):
1
0
2
#DatoDxd was approved on 1/17/25 for HR+ mBC in endocrine resistant settings. But recent update with no OS!!!! This slide shared by @stolaney1 does an excellent job showing data across different ADCs in this space. #bcsm #OncTwitter #MedTwitter
Dato-DXd, approved by the FDA 1 month ago, showed no difference in OS compared to TPC. In the Tropion-Breast 01 study, OS was a co-primary endpoint along with PFS. Since OS failed, can we still consider this a positive study? If PFS alone is enough for approval, does this mean OS is becoming less relevant?
0
14
42
Brentuximab Vedotin + R2 (Lenalidomide/Rituximab) now @FDAOncology approved for R/R DLBCL based off Ph3 #ECHELON3: - OS 13.8 mos BV+R2 vs 8.5mos - R2 alone as a comparator arm not ideal - ORR: 64% vs 42% - ≥ Gr3 AEs: 88% vs 77% #HemeTwitter #OncTwitter #MedTwitter
FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma #OCENewsBurst
1
11
35
RT @dr_yakupergun: ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric ju…
0
21
0
RT @SujayRainchwar: ⭐️ VTE And duration of anticoagulation Category of Major persistent risk factor, requiring long term anticoagulation.…
0
21
0
RT @doctorpemm: 👉👉👉WOW !! A Sizzling🔥 discussion about all things MPN this evening on @HemeReports !! You can still listen to the entire ep…
0
5
0